Press release
CRBSI Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Leonard-Meron Biosciences, Inc.
CRBSI Pipeline Analysis
DelveInsight reports that over five key companies are actively engaged in developing more than five treatment therapies for Catheter-related bloodstream infections (CRBSI).
Catheter-related bloodstream infection Overview:
Catheter-related bloodstream infection (CRBSI) occurs when bacteria enter the bloodstream through an intravenous catheter. It is one of the most frequent, serious, and costly complications associated with central venous catheter (CVC) use and stands as the leading cause of hospital-acquired bloodstream infections. Intravascular catheters play a vital role in modern healthcare-especially for critically ill patients-by enabling the delivery of fluids, medications, blood products, nutritional support, and hemodynamic monitoring.
However, central venous catheters present the highest risk for device-associated infections compared to other medical devices. They are a major contributor to hospital-acquired bacteremia and septicemia, leading to increased patient morbidity and mortality. Most CRBSI cases are linked to CVC use, with studies showing that the risk of CRBSI is up to 64 times greater with CVCs than with peripheral venous catheters.
Request for a detailed insights report on CRBSI pipeline insights [https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"CRBSI Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the CRBSI Therapeutics Market.
Key Takeaways from the CRBSI Pipeline Report
*
DelveInsight's CRBSI pipeline report highlights a dynamic landscape, with over five active companies engaged in developing more than five therapies targeting Catheter-related bloodstream infections (CRBSI). Key players, including Leonard-Meron Biosciences, Inc., are advancing novel treatment options aimed at enhancing CRBSI management. Among the notable therapies in the pipeline is Mino-Lok, which is currently in various stages of development.
*
A significant milestone was reached on November 15, 2023, when the U.S. FDA approved DefenCath Registered -the first and only FDA-approved antimicrobial catheter lock solution in the U.S.-for reducing the risk of CRBSIs in adult patients with kidney failure undergoing chronic hemodialysis via a central venous catheter.
CRBSI Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the CRBSI Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRBSI treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the CRBSI market.
Download our free sample page report on CRBSI pipeline insights [https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
CRBSI Emerging Drugs
*
Mino-Lok: Leonard-Meron Biosciences, Inc.
CRBSI Companies
Over five leading companies are currently working on developing therapies for Catheter-related Bloodstream Infection (CRBSI). Notably, Leonard-Meron Biosciences, Inc., along with several others, has drug candidates that have progressed to the most advanced stage of development-Phase III clinical trials.
DelveInsight's report covers around 5+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
CRBSI pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
CRBSI Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging CRBSI Therapies and Key Companies: CRBSI Clinical Trials and advancements [https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
CRBSI Pipeline Therapeutic Assessment
- CRBSI Assessment by Product Type
- CRBSI By Stage
- CRBSI Assessment by Route of Administration
- CRBSI Assessment by Molecule Type
Download CRBSI Sample report to know in detail about the CRBSI treatment market @ CRBSI Therapeutic Assessment [https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. CRBSI Current Treatment Patterns
4. CRBSI - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. CRBSI Late-Stage Products (Phase-III)
7. CRBSI Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. CRBSI Discontinued Products
13. CRBSI Product Profiles
14. CRBSI Key Companies
15. CRBSI Key Products
16. Dormant and Discontinued Products
17. CRBSI Unmet Needs
18. CRBSI Future Perspectives
19. CRBSI Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the CRBSI Pipeline Reports Offerings [https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=crbsi-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-leonardmeron-biosciences-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CRBSI Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Leonard-Meron Biosciences, Inc. here
News-ID: 4136014 • Views: …
More Releases from ABNewswire
Free Self Assessment UK | File Taxes Online with Pie
Pie is making tax season easier with its free self assessment UK tool, giving taxpayers the ability to file online with HMRC in minutes. From freelancers to side hustlers, Pie helps users avoid costly mistakes while ensuring compliance all without the heavy fees of traditional accountants.
LONDON, United Kingdom - 23 September, 2025 - With more than 12 million self assessment tax returns filed each year, UK taxpayers are searching for…
Best Digital Tax App UK | HMRC-Ready Filing with Pie
Pie is fast becoming recognised as the best digital tax app in the UK. With HMRC-ready submissions, real-time calculations, and an interface designed for simplicity, Pie is helping freelancers, landlords, and small businesses take control of their taxes.
LONDON, United Kingdom - 23 September, 2025 - As more people turn to mobile-first solutions for money management, Pie is gaining recognition as the best digital tax app in the UK, combining simplicity,…
Atopic Dermatitis Pipeline Drugs Report 2025 by DelveInsight Highlighting Curren …
DelveInsight's "Atopic Dermatitis Pipeline Insight 2025" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report now…
Breast Cancer Pipeline Drugs Report 2025 by DelveInsight Covering Evolving Resea …
DelveInsight's "Breast Cancer Pipeline Insight 2025" report provides comprehensive insights about 250+ Breast Cancer companies and 300+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest…
More Releases for CRBSI
Catheter-Related Bloodstream Infection (CRBSI) Market is expected to reach USD 3 …
Catheter-related bloodstream infections (CRBSIs) are among the most serious and common hospital-acquired infections, caused when pathogens enter the bloodstream through central venous catheters (CVCs), peripherally inserted central catheters (PICCs), or other intravascular devices. These infections significantly increase patient morbidity, hospital stays, and healthcare costs, making their prevention and treatment a top priority in modern healthcare.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71721
The market for CRBSI is expanding due…
Global CRBSI Treatment Market to Experience Significant Growth to reach USD 2,90 …
The global CRBSI treatment market is on a significant growth trajectory, projected to experience a compound annual growth rate (CAGR) of 5.4% between 2025 and 2035. This growth is being propelled by multiple factors, including the rising burden of hospital-acquired infections (HAIs), increased use of central venous catheters (CVC), and continual advancements in antimicrobial therapies. These key drivers, along with ongoing innovations in infection prevention and management, are expected to…
CRBSI Treatment Market Expected to Reach USD 2.2 Billion by 2030 | Persistence M …
The global catheter-related bloodstream infection (CRBSI) treatment market is poised for significant expansion, projected to rise from US$1.5 billion in 2023 to US$2.2 billion by 2030, reflecting a CAGR of 5.7%. The market's growth is driven by the rising prevalence of chronic diseases necessitating long-term catheter use, increased healthcare expenditures, and advancements in catheter technologies.
Among the various segments, antibiotic-based treatments hold the largest share, while the echinocandin antifungal segment is…
Catheter-Related Bloodstream Infection (CRBSI) Drugs Market Size, Share, Growth, …
Global Catheter-Related Bloodstream Infection (CRBSI) Drugs Market to Witness Substantial Growth by 2031
The global market for Catheter-Related Bloodstream Infection (CRBSI) drugs has shown remarkable growth in recent years, reaching US$ million in 2022. According to the latest industry analysis, this market is projected to surge to US$ million by 2031, with a robust Compound Annual Growth Rate (CAGR) of during the forecast period spanning 2024 to 2031.
CRBSI is…
Catheter-related bloodstream infection (CRBSI) Market Insight, Epidemiology and …
Catheter-related bloodstream infection (CRBSI) Market research report is the new statistical data source added by Infinity Business Insights.
CRBSIs (central venous catheter-related bloodstream infections) are a leading source of hospital-acquired illness, with high rates of morbidity, death, and expense. The severity of the consequences is determined by the organisms involved, the underlying pre-morbid states, the timeliness, and the suitability of the treatment/interventions received.
Note – In order to provide more accurate…
Catheter-related bloodstream infection (CRBSI) Market Insight, Epidemiology and …
Catheter-related bloodstream infection (CRBSI) Market research report is the new statistical data source added by Infinity Business Insights.
CRBSIs (central venous catheter-related bloodstream infections) are a leading source of hospital-acquired illness, with high rates of morbidity, death, and expense. The severity of the consequences is determined by the organisms involved, the underlying pre-morbid states, the timeliness, and the suitability of the treatment/interventions received.
Note – In order to provide more accurate…
